The male urinary incontinence treatment device “Cellution Cell Therapy Kit SUI,” manufactured by an ADR120S subsidiary, received formal approval under insurance coverage category C2, with the reimbursement price set at ¥860,000. Adoption by medical institutions may accelerate going forward.
The male stress urinary incontinence treatment device “Cellution Cell Therapy Kit SUI,” manufactured and sold by a subsidiary of the ADR120S Group, received formal approval for insurance coverage dated 16 September 2026. The treatment uses adipose tissue-derived regenerative cells (ADRCs), and is characterized by its use of the patient’s own cells.
The insurance coverage category is C2 (new function/new technology), and the reimbursement price payable to medical institutions was set at ¥860,000. As part of the approval process, the device received preliminary notice following deliberations by the Health Insurance Medical Materials Technical Committee on 7 August, followed by formal approval at a plenary meeting of the Central Social Insurance Medical Council on 16 September.
The treatment improves urinary incontinence by extracting adipose-derived ADRCs and injecting them around the urethra. Its main feature is that it does not require cell culturing and can be completed as a series of procedures, from liposuction through injection, in approximately 3 hours.
ADR120S has adopted a policy of accelerating the implementation of regenerative medicine in society and will launch a medical device rental business in Japan in October 2026 using a domestically produced version of its centrifuge. Insurance coverage is expected to reduce patients’ out-of-pocket costs and lower the barriers to adoption by medical institutions.